Characterizing genetic and phenotypic traits of early onset enteropathies
Official title: Host-Microbiota Interactions Across the Gut Immune System: Characterization of Phenotype and Genotype of Early Onset Enteropathies
Run by Imagine Institute · NCT02614911 · Data updated 2026-11-12
This study is trying to understand the genetic and physical traits of young children with early onset gut issues to see how their bodies handle gut health despite having many microbes.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1445 (estimated) |
| Sponsor | Imagine Institute Academic / other |
| Locations | 12 sites (Bordeaux and 11 other locations) |
| Status | Recruiting |
| Started | June 16, 2014 |
| Main results expected | June 15, 2054 |
| Study ends | June 15, 2054 |
| Registry record updated | April 30, 2025 |
| Trial ID | NCT02614911 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with severe chronic enteropathy who show symptoms early in life, particularly within the first two years.
✕Probably not a fit
Patients who have participated in any therapeutic clinical study within the last 30 days may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on understanding the phenotypes and genotypes of patients with early onset enteropathies, particularly those who develop symptoms within the first six years of life. Investigators will collect biological samples, primarily blood, from affected patients and their healthy relatives to analyze genetic factors. The goal is to identify human pathways that help maintain intestinal health despite the presence of numerous microbes in the gut. This research aims to provide insights into the underlying mechanisms of inflammatory bowel disease in young patients.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of early onset enteropathies, potentially guiding future treatments.
How similar studies have gone: While this study is focused on a specific population, similar genetic characterization studies have shown promise in understanding complex conditions, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Main Inclusion Criteria: * Severe chronic enteropathy * Patients developing their first symptoms within the first 6 years of life and, in priority within the first two years of life, or patients with a disease of later onset, in case of a familial history suggestive of inherited mutations notably in families comprising several affected members * OR : Be a patient's relative, even if presenting with enteropathy of later onset. Main Exclusion Criteria: * Subject having participated to any therapeutical clinical study in the 30 days preceding the inclusion in this study,
Where it's running
-
Centre Hospitalier Pellegrin-Enfants
Bordeaux, France Recruiting -
Hôpital pédiatrique de Lyon
Bron, France Recruiting -
Hôpital Jeanne de Flandre, CHRU de Lille
Lille, France Recruiting -
Hôpital d'enfants de la Timone
Marseille, France Recruiting -
Hôpital Saint Antoine
Paris, France Recruiting -
Necker - Enfants Malades Hospital
Paris, France Recruiting
Show 6 more locations
-
Hôpital Robert Debré
Paris, France Recruiting -
Hôpital Trousseau
Paris, France Recruiting -
Hôpital Sud
Rennes, France Recruiting -
Hôpital des Enfants
Toulouse, France Recruiting -
Hôpital Clocheville, CHU de Tours
Tours, France Recruiting -
CHU Hautepierre
Strasbourg, France Not yet recruiting
Study contacts
- Principal investigator: Frank Ruemmele — Necker - Enfants Malades Hospital
- Study coordinator: Nadine Cerf-Bensussan
- Email: nadine.cerf-bensussan@inserm.fr
- Phone: + 33 1 42 75 42 88
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fecal Transplants from Dai vs Han Donors for Ulcerative Colitis
This study tests whether fecal microbiota transplantation from healthy Dai donors improves symptoms in adults with ulcerative colitis more than transplantation from healthy Han donors.
-
Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease
This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.
-
Breast milk mirikizumab levels in lactating people using mirikizumab for IBS/IBD
This study tests how much mirikizumab passes into breast milk for people who are breastfeeding while on mirikizumab for an approved condition.
-
Real-world use of guselkumab in Crohn’s disease and ulcerative colitis
This study tests how long guselkumab stays in the bodies of adults with moderate-to-severe Crohn’s disease or ulcerative colitis treated in real-world clinical settings.
-
Gut microbiome and metabolites in people with IBD and depression
This project will test whether gut microbes and metabolites differ in adults with IBD who have depression compared with those without depression and with healthy adults.
-
Real-world use of guselkumab for adults with moderate-to-severe ulcerative colitis and Crohn's disease in the UK
This project will see how well guselkumab works for adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting the treatment in routine UK care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.